Eisai Signs a Research Agreement with Cerveau Technologies for its Novel Tau Imaging Agent

Shots:

• Eisai & Cerveau Technologies enter into a research collaboration to utilize Cerveau’s [F-18]MK-6240 in PET scan for assessing the status of neurofibrillary tangles (NFTs) in the brain
• The focus of the collaboration is to utilize Cerveau’s [F-18]MK-6240 as a biomarker and to evaluates its effect in Eisai’s neurodegenerative research studies
• Cerveau’s MK-6240 is a positron emission tomography (PET) used to scans neurofibrillary tangles (NFTs) in the brain. Cerveau Technologies also collaborated with Enigma Biomedical & Sinotau Pharmaceutical for its imaging agent

Click here to read full press release/ article | Ref: BusinessWire | Image: Bizjournals